Skip to main content
    G

    GeoVax Labs Inc (GOVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.02
    +0.32 (+18.48%)

    Market Cap: $928,290

    Last updated: Nov 17, 2026 at 11:04 AM ET

    GeoVax Labs Inc (GOVX) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    GeoVax Labs (GOVX) is expected to report earnings on Apr 13, 2027. In the quarter ended Sep 30, 2026, GeoVax Labs reported EPS of -$10.56, above the -$24.58 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(16/32)
    Avg Surprise
    -2.63%
    Streak
    2 Q

    Upcoming Estimates

    Reports Apr 13, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$29.38
    RangeN/A
    3 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    GOVX has an expected report date of Apr 13, 2027.

    GOVX Earnings Call

    The latest GOVX earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    Earnings History

    Of the 33 quarters below that had an estimate, GOVX beat 16, missed 7 and matched 10. The widest gap in the table came in the quarter ended Dec 31, 2021, when EPS landed 457.50% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$10.56-$24.58N/A+57.04%BeatN/A1N/ANov 12, 2026N/A
    Jun 30, 2026-$0.97-$2.16-$2.88 - -$1.43+55.09%BeatN/A2N/AJul 27, 2026N/A
    Mar 31, 2026-$2.62-$0.84-$1.60 - -$0.09-211.90%MissN/A21 up, 0 downApr 2, 2026N/A
    Sep 30, 2025-$7.75-$6.62-$8.00 - -$5.75-17.07%MissN/A43 up, 0 downNov 13, 2025N/A
    Jun 30, 2025-$8.75-$9.00N/A+2.78%BeatN/AN/A0 up, 0 downJul 28, 2025$852282
    Mar 31, 2025-$11.25-$16.44N/A+31.57%BeatN/AN/A0 up, 0 downMay 1, 2025$1.64M
    Dec 31, 2024-$0.30-$0.77N/A+60.94%BeatN/AN/A0 up, 0 downMar 27, 2025$864415
    Sep 30, 2024-$22.75-$32.90-$51.00 - -$22.75+30.85%BeatN/A40 up, 0 downNov 12, 2024$2.79M
    Jun 30, 2024-$49.75-$84.12-$145.50 - -$52.50+40.86%BeatN/A40 up, 0 downAug 6, 2024$300677
    Mar 31, 2024-$2.47-$5.56-$5.56 - -$5.56+55.58%BeatN/A10 up, 0 downMay 14, 2024N/A
    Dec 31, 2023-$98.50-$105.00-$1,911.54 - $26.24+6.19%BeatN/A31 up, 0 downFeb 29, 2024$103912
    Sep 30, 2023-$120.00-$90.00-$93.70 - -$86.21-33.33%MissN/A30 up, 0 downNov 8, 2023N/A
    Jun 30, 2023-$82.50-$63.75N/A-29.41%MissN/A40 up, 0 downAug 9, 2023N/A
    Mar 31, 2023-$56.25-$84.37-$89.96 - -$59.97+33.33%BeatN/A30 up, 0 downMay 4, 2023N/A
    Dec 31, 2022-$0.20-$0.20-$0.25 - -$0.170.00%In lineN/A30 up, 0 downMar 23, 2023N/A
    Sep 30, 2022-$63.75-$45.00N/A-41.67%MissN/A10 up, 0 downNov 9, 2022N/A
    Jun 30, 2022-$67.50-$112.50N/A+40.00%BeatN/AN/A0 up, 0 downAug 3, 2022N/A
    Mar 31, 2022-$127.50-$116.25N/A-9.68%MissN/A10 up, 0 downApr 27, 2022$81526
    Dec 31, 2021-$2.23-$0.40-$0.40 - -$0.40-457.50%Miss-100.8%10 up, 0 downMar 9, 2022$164962
    Sep 30, 2021-$116.25-$138.75N/A+16.22%BeatN/A1N/ANov 11, 2021$30414
    Jun 30, 2021-$78.75-$161.25N/A+51.16%BeatN/A1N/AAug 11, 2021$79708
    Mar 31, 2021-$0.29-$0.29N/A0.00%In lineN/AN/AN/AMay 6, 2021$110417
    Dec 31, 2020$266.25-$15.00N/AN/AN/AN/AN/AN/AMar 23, 2021$251621
    Sep 30, 2020-$0.73-$0.73N/A0.00%In lineN/AN/AN/ANov 5, 2020$415458
    Jun 30, 2020-$0.03-$0.03N/A0.00%In lineN/AN/AN/AAug 10, 2020$440602
    Mar 31, 2020-$0.13-$0.13N/A0.00%In lineN/AN/AN/AMay 5, 2020$715977
    Dec 31, 2019-$2.52-$1,040.00N/A+99.76%BeatN/AN/AN/AMar 24, 2020$268514
    Sep 30, 2019-$449,999.77-$1,000,000.00N/A+55.00%BeatN/AN/AN/ANov 7, 2019$333209
    Jun 30, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 14, 2019$209941
    Mar 31, 2019-$57,200.00N/AN/AN/AN/AN/AN/AN/AMay 13, 2019$364232
    Dec 31, 2018-$1,000,000.00N/AN/AN/AN/AN/AN/AN/AMar 27, 2019$299295
    Sep 30, 2018-$1.99N/AN/AN/AN/AN/AN/AN/ANov 8, 2018$349344
    Jun 30, 2018-$2.05N/AN/AN/AN/AN/AN/AN/AAug 7, 2018$93265
    Mar 31, 2018-$200,000.00N/AN/AN/AN/AN/AN/AN/AMay 3, 2018$221299
    Dec 31, 2017-$200,000.00-$1,000,000.00N/A+80.00%BeatN/AN/AN/AMar 23, 2018$179404
    Sep 30, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/ANov 9, 2017$247994
    Jun 30, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 7, 2017$352137
    Mar 31, 2017-$0.01N/AN/AN/AN/AN/AN/AN/AMay 8, 2017$295735
    Dec 31, 2016-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AMar 24, 2017$174932
    Sep 30, 2016-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/ANov 11, 2016$440106
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$27.75, after -$75.27 the year before. It was -$3,749,302.88 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$27.75N/A
    Dec 31, 2024-$75.27N/A
    Dec 31, 2023-$357.25N/A
    Dec 31, 2022-$258.95N/A
    Dec 31, 2021-$197.52-174.4%
    Dec 31, 2020$265.36N/A
    Dec 31, 2019-$1,507,202.29N/A
    Dec 31, 2018-$1,200,004.04N/A
    Dec 31, 2017-$2,200,000.01N/A
    Dec 31, 2016-$3,749,302.88N/A

    Earnings Calls

    The 4 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 3,400 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q3Sep 30, 20253,4418
    2025Q2Jun 30, 20254,5259
    2025Q1Mar 31, 20254,2307
    2024Q3Sep 30, 20246,87413

    2025Q3 Earnings Call

    Opening remarks

    David Dodd CEO Thank you. Welcome to the third quarter 2025 GeoVax corporate update. Following my comments, Mark Reynolds, our CFO, will provide an update of our financials, and then we will address any questions that you may have. We remain confident in the continued progress and compelling outlook for our portfolio of GEO-MVA, GEO-CM04S1, Gedeptin and the game-changing MVA vaccine manufacturing process. Each of our product development candidates address critically important unmet health care needs, providing opportunities for expedited registration paths and strong opportunities to commercialize differentiated solutions supporting patient needs worldwide. We also anticipate that the advanced MVA manufacturing process will provide a game-changing advantage in the production of MVA-based vaccines and therapies. We're experiencing increased partnering and collaboration interest from established industry players as well as increased interest from non-dilutive funding organizations, including stakeholders addressing various areas of worldwide vaccine needs. In June, we announced the receipt of guidance from the European Medicines Agency, referred to as the EMA, providing an expedited development path for GEO-MVA, our vaccine candidate against Mpox and Smallpox. This is most encouraging news in that it provides the potential for GeoVax to achieve marketing authorization and revenue generation sooner, allowing us to bypass Phase I and Phase II clinical trials and proceed directly to a Phase III immuno-bridging trial. As a result of this news, we're experiencing increased interest and dialogue with various industry colleagues and stakeholders regarding potential partnering, collaboration and funding. Relative to GEO-MVA, we have initiated the fill/finish of clinical batch vaccine material. We anticipate having vaccine available for clinical evaluation early next year. We're pleased to note that in addition to product in support of our clinical evaluation, we plan to produce additional product in support of potential use in conjunction with various stakeholder discussions that are underway. We believe that GEO-MVA provides the potential to end the current monopoly of MVA vaccine supply, expanding the global supply of this critically needed vaccine, addressing both the needs resulting from epidemic outbreaks as well as the various stockpile opportunities worldwide. Significant government interest exists relative to U.S.-based supply chains versus the current overdependence on non-U.S. suppliers. The strong sentiment in favor of such onshoring initiatives is a major national legislative focus and interest. We remain in active discussions and briefings with various stakeholders, including the White House, Congressional Representatives, HHS, WHO, the International Vaccine Institute, the Africa CDC and others regarding our progress relative to cGMP clinical inventory of GEO-MVA. In fact, this was the subject of numerous discussions during our recent series of meetings in Europe in conjunction with the World Vaccine Congress Europe, BIO-Europe and individual meetings held in Geneva and elsewhere.

    Frequently Asked Questions About GOVX

    When is GeoVax Labs's next earnings date?

    GeoVax Labs's next earnings report is expected for Apr 13, 2027.

    Did GOVX beat earnings estimates last quarter?

    Yes. GeoVax Labs reported EPS of -$10.56 for the quarter ended Sep 30, 2026, above the -$24.58 estimate, a 57.04% surprise.

    What EPS do analysts expect from GOVX next quarter?

    The consensus EPS estimate for GeoVax Labs for the quarter ending Dec 31, 2026 is -$29.38 from 3 analysts.

    How often does GOVX beat earnings estimates?

    GeoVax Labs beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +1.16%.